相关实验视频

Updated: Jan 15, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

在移植后新诊断的多发性骨髓瘤中,达拉图穆马布加列纳利多米德的维持:AURIGA子组分析

Laahn Foster¹, Larry D Anderson², Alfred Chung³

¹Division of Hematology Oncology, University of Virginia, Charlottesville, VA, USA. LF5V@uvahealth.org.

Blood cancer journal

|October 6, 2025

概括

达拉图穆马布-莱纳利多米德的维护显著改善了MRD阴性转化,并降低了新诊断的多发性骨髓瘤患者的进展风险,包括高危子组. 这种好处在不同年龄和种族之间是一致的,没有增加安全问题.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床试验临床试验

背景情况:

多发性骨髓瘤 (MM) 是一种血液性恶性瘤.
维持疗法旨在延长缓解期并改善结果.
风险分层对于定制MM治疗至关重要.

研究的目的:

在新诊断的MM患者中,评估daratumumab-lenalidomide (D-R) 维护与lenalidomide (R) 维护的疗效.
在子组中评估D-R维护,包括具有高风险细胞遗传异常 (HRCAs) 的子组.
根据不同的细胞遗传风险标准 (原始,修订,修改的IMS2024) 分析结果.

主要方法:

随机3期AURIGA研究的后期分析.
在D-R和R维护臂之间对MRD负转换率和无进展生存率 (PFS) 的比较.
基于细胞遗传风险,年龄和种族的子组分析.

主要成果:

与R维护相比,D-R维护在所有细胞遗传风险亚组中显著提高了MRD负转化率.
在具有D-R的高风险和超高风险细胞遗传亚组中观察到更高的MRD负转化率.
在高风险小组中,D-R显示了改善PFS的趋势,在老年或黑人患者中没有额外的安全问题.

结论:

在新诊断的MM患者中,达拉图穆马布-莱纳利多米德的维持在实现MRD阴性方面提供了显著的好处,特别是那些具有高风险细胞遗传的患者.
在各种风险状态,年龄组和种族中,D-R维护的有效性是一致的.
这些发现支持D-R维护作为一种有价值的治疗策略,用于广泛的新诊断的MM患者.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.